Caris Life Sciences partners with Debiopharm International SA

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.

July 10, 2026

By Enrique Velazquez-Villarreal

The long life of a clinical trial
How JCO sustains landmark oncology research

In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.

July 10, 2026

By Journal of Clinical Oncology

Cancer Policy

FDA halts public release of Complete Response Letters, following citizen petition

FDA will temporarily stop publicly releasing rejection letters as it evaluates potential response to a citizen petition issued by an unnamed pharmaceutical company challenging the legality of the practice.

July 10, 2026

By Claire Marie Porter

Cancer Policy

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Medicare Advantage beneficiaries have access to fewer cancer specialists, when compared to traditional Medicare beneficiaries, according to a study published in JAMA Network Open.

July 10, 2026

By Sara Willa Ernst

Cancer Policy

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

The Centers for Medicare & Medicaid Services has proposed a sweeping new Advance Care Planning quality measure (MUC2025-020) that would track end-of-life care discussions for patients 18 and older.

July 10, 2026

By Claire Marie Porter

Cancer Policy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

FDA has issued a proposed rule to require both foreign and domestic tobacco manufacturers to register their facilities and list their products with the agency. This closes a regulatory gap, holding overseas e-cigarette and tobacco makers to the same standards as U.S. companies.

July 10, 2026

By Claire Marie Porter

Caris Life Sciences partners with Debiopharm International SA

YOU MAY BE INTERESTED IN

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

The long life of a clinical trial
How JCO sustains landmark oncology research

FDA halts public release of Complete Response Letters, following citizen petition

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

Renew today!

Subscriber content

Never miss an issue!

Login

Caris Life Sciences partners with Debiopharm International SA

YOU MAY BE INTERESTED IN

The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine

The long life of a clinical trialHow JCO sustains landmark oncology research

FDA halts public release of Complete Response Letters, following citizen petition

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

Never miss an issue!

Login

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

The long life of a clinical trial
How JCO sustains landmark oncology research